Roche moved deeper into obesity with a deal for Hanmi Pharm’s clinical-stage urocortin-2 analog. Roche agreed to an upfront payment of $190 million for the asset, adding a less-explored mechanism to its obesity pipeline and signaling continued willingness to fund mechanism diversification beyond GLP-1-class targets. The transaction also highlights how mid-stage nontraditional metabolic biology is attracting premium valuation, particularly when data suggest the target pathway could complement existing standards of care. For Hanmi, the funding provides runway to advance a program that already sits in the clinic. The news lands as obesity remains one of the biotech sector’s most competitive therapeutic areas, with investors focused on differentiation, duration of benefit, and combination potential.